Clinical trials: Controlled Diabetes
Obesity
BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus
The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients with Type II diabetes mellitus treated with metformin, sulfonylurea (SFU)…
- Trial name
- NCT00603291
- Testing
- Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID)
- Where
- United States
- Volunteers
- 604 people
- Sponsor
- Eisai Inc.
Type 2 Diabetes Mellitus
Treatment of Diabetes After Gastric Bypass With Sitagliptin
The purpose of this study is to assess whether Januvia (sitagliptin phosphate 100mg) is safe and effective for the treatment of Type 2 Diabetes in patients who have had Gastric Bypass.
- Trial name
- LAF33 (NCT01512797)
- Testing
- Sitagliptin phosphate
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Blandine Laferrere
Diabetic Foot Ulcer
Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers
The purpose of this study is to determine safety and efficacy of a new gel formulation of Esmolol hydrochloride (Galnobax®) for the treatment of Diabetic Foot Ulcer (DFU).
- Trial name
- NCT01113515
- Testing
- Esmolol hydrochloride
- Where
- 5 sites in United States, India and 1 more
- Volunteers
- 44 people
- Sponsor
- Novalead Pharma Private Limited
Type 2 Diabetes
Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes
The purpose of this study is to assess the effect of roflumilast plus alogliptin on glucagon-like peptide-1 (GLP-1) and glucose levels in patients with type 2 diabetes.
- Trial name
- NCT01664624
- Testing
- Roflumilast, Alogliptin, Exenatide
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes
The purpose of this study is to learn if BMS-512148 (Dapagliflozin) as part of a triple combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes after 24 weeks of treatment compared to a 2 drug…
- Trial name
- NCT01646320
- Testing
- Dapagliflozin, Saxagliptin, Metformin immediate release (IR)
- Where
- 66 sites in United States, Czechia and 6 more
- Volunteers
- 320 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
BI 10773 add-on to Metformin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and pharmacokinetics of five doses of BI 10773 compared to placebo given for 12 weeks as add-on therapy to on going metformin therapy in patients with T2DM…
- Trial name
- NCT00749190
- Testing
- BI 10773, sitagliptin
- Where
- 116 sites in United States, Argentina and 14 more
- Volunteers
- 495 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 1
A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)
This study compares insulin icodec (a new insulin) to insulin degludec (an insulin already available on the market) in people with type 1 diabetes.
- Trial name
- ONWARDS 6 (NCT04848480)
- Testing
- insulin icodec, insulin degludec, insulin aspart
- Where
- 130 sites in United States, Austria and 10 more
- Volunteers
- 582 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes
Cycloset, a new quick-release oral formulation of bromocriptine mesylate, effectively reduces blood sugar by the proposed mechanism of reversing many of the metabolic alterations associated with insulin resistance and obesity by…
- Trial name
- NCT00377676
- Testing
- Cycloset
- Volunteers
- 3,095 people
- Sponsor
- VeroScience
Children and Adolescent With Type 2 Diabetes
Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes
The study examines the Safety and efficacy study of exenatide once weekly in children and adolescents with type 2 diabetes
- Trial name
- NCT01554618
- Testing
- Exenatide Once Weekly
- Where
- 35 sites in United States, Bulgaria and 5 more
- Volunteers
- 84 people
- Sponsor
- AstraZeneca
Diabetes, Glycemic Control
The VA Diabetes Trial Follow-up Study (VADT-FS)
CSP #465, "Glycemic Control and Complications in Diabetes Mellitus Type 2," was a randomized unblinded clinical trial comparing tight glycemic control to standard glycemic control.
- Trial name
- VADT-F (NCT00756613)
- Where
- 2 sites in United States
- Volunteers
- 1,044 people
- Sponsor
- VA Office of Research and Development
Type 1 Diabetes Mellitus
The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas
The objective of the study is to assess efficacy and safety of a closed loop system (t:slim X2 with Control-IQ Technology) in a large randomized controlled trial.
- Trial name
- DCLP3 (NCT03563313)
- Testing
- t:slim X2 with Control-IQ Technology & Dexcom G6 CGM, Sensor-augmented pump (SAP)
- Where
- 7 sites in United States
- Volunteers
- 168 people
- Sponsor
- University of Virginia
Type 2 Diabetes Mellitus, CKD and Albuminuria
A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD
The purpose of this clinical research study is to determine whether dapagliflozin alone or in combination with saxagliptin can decrease albuminuria and improve glycemic control in patients with Type 2 diabetes, albuminuria and…
- Trial name
- NCT02547935
- Testing
- Dapagliflozin 10 mg, Saxagliptin 2.5 mg
- Where
- 112 sites in United States, Australia and 7 more
- Volunteers
- 459 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
The aim of this study is to investigate the efficacy and safety of two doses (high and low) of empagliflozin as add-on therapy to metformin in patients with type 2 diabetes mellitus (T2DM) and insufficient glycaemic control.
- Trial name
- NCT01649297
- Testing
- empagliflozin (low dose qd), Empagliflozin (high dose qd), empagliflozin (high dose bid)
- Where
- 139 sites in United States, Australia and 16 more
- Volunteers
- 983 people
- Sponsor
- Boehringer Ingelheim
Coronary Artery Disease
Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following Core 64
Patients with a known history of diabetes mellitus and no prior documented evidence of cardiovascular disease will be evaluated for inclusion in the study.
- Trial name
- faCTor-64 (NCT00488033)
- Testing
- CT Angiography
- Where
- United States
- Volunteers
- 900 people
- Sponsor
- Intermountain Health Care, Inc.
Diabetes Mellitus, Type 2
Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy of fasiglifam (TAK-875) plus metformin compared with sitagliptin plus metformin on glycemic control over a 24-week Treatment Period.
- Trial name
- NCT01834274
- Testing
- Fasiglifam (TAK-875), Sitagliptin, Metformin
- Where
- 104 sites in United States, Argentina and 11 more
- Volunteers
- 96 people
- Sponsor
- Takeda
Diabetic Kidney Disease
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
The primary objective of this study is to determine the effect of selonsertib (formerly GS-4997) on estimated glomerular filtration rate (eGFR) decline in participants with diabetic kidney disease (DKD).
- Trial name
- NCT02177786
- Testing
- Selonsertib
- Where
- 105 sites in United States, Canada
- Volunteers
- 334 people
- Sponsor
- Gilead Sciences
Diabetes Mellitus, Type 2
Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies
The study is a comparison of twice-daily insulin lispro low mixture versus once-daily basal insulin glargine and once-daily prandial insulin lispro, in participants with Type 2 Diabetes.
- Trial name
- NCT01175824
- Testing
- Insulin Lispro Low Mixture (LM), Insulin Glargine, Prandial Insulin Lispro
- Where
- 18 sites in Argentina, Brazil and 6 more
- Volunteers
- 478 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Control-IQ Observational (CLIO) Post-Approval Study
Post-approval 522 study designed to collect primarily safety data on the US FDA-cleared product, t:slim X2 insulin pump with Control-IQ technology (Control-IQ system).
- Trial name
- CLIO (NCT04503174)
- Testing
- t:slim X2 pump with Control-IQ technology
- Where
- United States
- Volunteers
- 3,157 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study
This is a randomized, double-blind, double-dummy, placebo-controlled, cross over design trial with empagliflozin compared to placebo that is added to open-label ramipril.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Obesity
- Trial name
- NCT02632747
- Testing
- Empagliflozin, ramipril
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Effectiveness and Safety of Adding Compound Preparation of Pioglitazone and Metformin for Type 2 Diabetic Patients
Secondary failure of sulfonylureas (SUs) can occur in about 30%-40% of type 2 diabetic patients after treatment with SUs for 5 years, although SUs are widely used in type 2 diabetic patients.
- Trial name
- NCT02099838
- Testing
- Pioglitazone and Metformin
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Huazhong University of Science and Technology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.